263 related articles for article (PubMed ID: 34874631)
1. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
[TBL] [Abstract][Full Text] [Related]
2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
4. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
[TBL] [Abstract][Full Text] [Related]
6. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Shi T; Yin S; Zhu J; Zhang P; Liu J; Zhu Y; Wu S; Chen X; Wang X; Teng Y; Zhu T; Yu A; Zhang Y; Feng Y; Huang H; Bao W; Li Y; Jiang W; Zhang P; Li J; Ai Z; Zhang W; Jia H; Zhang Y; Jiang R; Zhang J; Gao W; Luan Y; Zang R
J Gynecol Oncol; 2020 May; 31(3):e61. PubMed ID: 32319233
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
10. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
11. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
Muallem MZ; Gasimli K; Richter R; Almuheimid J; Nasser S; Braicu EI; Sehouli J
Anticancer Res; 2015 Jun; 35(6):3423-9. PubMed ID: 26026105
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
14. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
15. Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
Int J Gynecol Cancer; 2023 Sep; 33(9):1440-1447. PubMed ID: 37567595
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.
Zou R; Jiang Q; Luo X; Chen M; Yuan L; Yao L
World J Surg Oncol; 2023 Nov; 21(1):375. PubMed ID: 38037085
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
[TBL] [Abstract][Full Text] [Related]
20. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.
Ding T; Tang D; Xi M
J Ovarian Res; 2021 Jul; 14(1):93. PubMed ID: 34256813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
